Compressible resilient granules and formulations prepared therefrom

• US 20070212417A1
• Filed: 03/07/2007
• Published: 09/13/2007
• Est. Priority Date: 03/07/2006
• Status: Abandoned Application

• Current Assignee: Capricorn Pharma Incorporated
• Original Assignee: Capricorn Pharma Incorporated
• Inventors: Cherukuri, S.
• Application Number:
  US11/715,821
• Publication Number:
  US 20070212417A1
• Time in Patent Office: Days
• US Class Current: 424/471
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/51 Thiamines, e.g. vitamin B1
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/205 Polysaccharides, e.g. alginate, gums; Cyclodextrin

Abstract

Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %; a sugar alcohol in an amount of about 15 wt % to about 35 wt %; and a binder having a viscosity from about 5000 mPa·s to about 250,000 mPa·s in an amount of from about 10 wt % to about 35 wt %, is capable of low-pressure, reversible agglomeration. In other embodiments, an oral dosage form of such granules and methods of administering said forms are provided.

Claims

1. A resilient self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %;

and a binder having a viscosity from about 5,000 mPa·

s to about 250,000 mPa·

s in an amount of from about 10 wt % to about 35 wt %, that is capable of low-pressure, reversible agglomeration.

2. The granule of claim 1, further comprising a sugar alcohol in an amount of about 15 wt % to about 35 wt %, wherein the sugar alcohol is selected from the group consisting of arabitol, erythritol, hydrogenated starch hydrolysates, isomalt, lactitol, maltitol, mannitol, sorbitol, xylitol, galactitol, inositol, ribitol, dithioerythritol, dithiothreitol, glycerol, derivatives thereof, and mixtures thereof.

3. The granule of claim 2, wherein the sugar alcohol is maltitol.

4. The granule of claim 1, wherein the polysaccharide is selected from the group consisting of simple sugars, complex sugars, fibers, starches, pectins, dextrans, dextrins, natural gums, synthetic gums, mucilages, derivatives thereof, components thereof, and mixtures thereof.

5. The granule of claim 4, wherein the polysaccharide is a dextrin.

6. The granule of claim 5, wherein the dextrin is maltodextrin.

7. The granule of claim 1, further comprising an active agent selected from the group consisting of analgesics;

anti-inflammatory agents;

anthelmintics;

anti-arrhythmic agents;

antibiotics including penicillins;

anticoagulants;

antidepressants;

antidiabetic agents;

antiepileptics;

antihistamines;

antihypertensive agents;

antimuscarinic agents;

antimycobacterial agents;

antineoplastic agents;

immunosuppressants;

antithyroid agents;

antiviral agents;

anxiolytic sedatives including hypnotics and neuroleptics;

astringents;

beta-adrenoceptor blocking agents;

blood products and substitutes;

cardiac inotropic agents;

contrast media;

corticosteroids;

cough suppressants including expectorants and mucolytics;

diagnostic agents;

diagnostic imaging agents;

diuretics;

dopaminergics including antiparkinsonian agents;

haemostatics;

immunological agents;

lipid regulating agents;

muscle relaxants;

parasympathomimetics;

parathyroid calcitonin and biphosphonates;

prostaglandins;

radio-pharmaceuticals;

sex hormones including steroids;

anti-allergic agents;

stimulants and anoretics;

sympathomimetics;

thyroid agents;

vasodilators;

xanthines;

antitussives;

decongestants;

alkaloids;

laxatives;

antacids;

ion exchange resins;

anti-cholesterolemics;

antipyretics;

analgesics including acetaminophen, aspirin, non-asteroidal anti-inflammatory drugs (“

NSAID”

) and opioids;

appetite suppressants;

expectorants;

anti-anxiety agents;

anti-ulcer agents;

coronary dilators;

cerebral dilators;

peripheral vasodilators;

anti-infectives;

psycho-tropics;

antimanics;

stimulants;

gastrointestinal agents;

sedatives;

anti-diarrheal preparations;

anti-anginal drugs;

vasodilators;

vasoconstrictors;

migraine treatments;

tranquilizers;

anti-psychotics;

antitumor drugs;

antithrombotic drugs;

hypnotics;

anti-emetics;

anti-nausants;

anti-convulsants;

neuromuscular drugs;

hyper- and hypoglycemic spasmodics;

uterine relaxants;

antiobesity drugs;

anabolic drugs;

erythropoetic drugs;

antiasthmatics;

mucolytics;

anti-uricemic drugs; and

mixtures thereof.

8. The granule of claim 7, wherein the active agent is selected from the group consisting of:

an analgesic, an antibiotic, a lipid regulating agent, an antihistamine, an antineoplastic agent, and an antiviral agent.

9. The granule, of claim 7, wherein the active agent is homogenous throughout the granule.

10. The granule of claim 7, wherein the active agent is coated on the surface of the granule.

11. The granule of claim 7, wherein the active agent is configured for controlled release.

12. The granule of claim 7, wherein the active agent is configured for immediate release.

13. The granule of claim 1, further comprising an additional additive selected from the group consisting of filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and mixtures thereof.

14. The granule of claim 1, wherein the binder is selected from the group consisting of syrups, emulsifiers, fats, waxes, gums, plasticizers, and mixtures thereof.

15. The granule of claim 14, wherein the binder is selected from the group consisting of maltitol syrups;

acetylated mono-, di-, or triglycerides;

polyethyleneglycol esters;

bees wax, carnuba wax;

spermaceti;

mineral oils;

paraffins;

microcrystalline waxes;

polyethylene wax;

gum Arabica;

gum tragacanth;

gum acacia;

fiber gums; and

mixtures thereof.

16. The granule of claim 15, wherein the binder is maltitol syrup.

17. The granule of claim 15, wherein the binder has a viscosity of at least about 10,000 mPa·

s.

18. The granule of claim 1, further comprising a nutritional supplement selected from the group consisting of calcium-containing materials, stannol esters, hydroxycitric acid, vitamins, minerals, herbals, spices and mixtures thereof.

19. The granule of claim 18, wherein the vitamin is selected from the group consisting of, vitamin A, vitamin D, vitamin E group, vitamin K group including phylloquinones and menaquinones, thiamine, riboflavin, niacin, folic acid, cobalamins, biotin, vitamin C, and mixtures thereof.

20. The granule of claim 18, wherein the nutritional supplement is a calcium-containing material, a zinc-containing material or vitamin C.

21. The granule of claim 1, wherein the granules agglomerate at a pressure of about 6500 kilonewtons/m².

22. The granule of claim 21, wherein the granules withstand compression pressures of about 40 kilonewtons without losing their resiliency.

23. The granule of claim 1, wherein the granules withstand compression pressures of about 50 kilonewtons without losing their resiliency.

24. The granule of claim 1, wherein the granule is produced by mixing and heating the binder, polysaccharide, and sugar alcohol in a mixer to form a reaction mixture, mixing for about 10 minutes, extruding the reaction mixture, cooling to room temperature for about 6-8 hours, milling to a particular granule size, and cooling in a freezer.

25. The granule of claim 1, wherein the granule is lubricated with a lubricant, and further modified with sweeteners, flavors and/or colorants.

26. An oral dosage composition, comprising a plurality of resilient granules as recited in claim 1, wherein the granules are combined into an oral dosage composition.

27. The composition of claim 26, wherein the plurality of resilient granules further comprises active agents homogenous throughout or coated thereon.

28. The composition of claim 27, wherein the granules contain a plurality of active agents present in a single granule or individually present in individual granules.

29. The composition of claim 28, wherein the granules are configured for immediate release, controlled release, or mixtures thereof.

30. The composition of claim 29, further comprising granules without active agents.

31. The composition of claim 26, wherein the granules are admixed with non-resilient granules having an active agent.

32. The composition of claim 26, wherein the oral dosage composition is a tablet or a semi-solid oral composition.

33. The composition of claim 32, wherein the tablet has been scored at least once.

34. The composition of claim 33, wherein the tablet is broke into two portions approximately defined by the scoring, and said breaking results in substantially no material loss.

35. The composition of claim 34, wherein the two portions are reformed with substantially no material loss.

36. Method of administering an active agent to a subject comprising,

a) providing the active agent in an oral dosage form, said oral dosage form comprises resilient granules as recited in claim 1,

b) administering the oral dosage form to the subject'"'"'s oral cavity, wherein the majority of the active agent is released in the gastrointestinal tract at a point after the mouth.

37. The method of claim 36, wherein the active agent is present in the resilient granules.

38. The method of claim 36, wherein the active agent is present in a non-resilient granule form.

39. The method of claim 36, wherein the oral dosage form is a tablet.

40. The method of claim 39, wherein the tablet is scored at least once.

41. The method of claim 40, the tablet is administered by breaking the tablet into two portions approximately defined by the scoring, and said breaking results in substantially no material loss.

42. The method of claim 36, wherein the oral dosage form is not a chewing gum.

43. The composition of claim 7, wherein the lubricating agent comprises greater than about 2% w/w of the composition

44. The composition of claim 43, wherein the lubricating agent is silicon dioxide.